The Rules Are Changing - Are You Ready? What the New Administration Means for Health & Life Science Innovators

Join Grant Engine and Healthcare Innovation Catalysts for a candid, strategic conversation on what lies ahead in 2025 for healthcare and life sciences innovators.

With a new federal administration and shifting policies at every level, 2025 is already proving to be a year of transformation for innovators in healthcare and life sciences. As regulations evolve and the funding landscape is redefined, understanding how to navigate your path with the government is more essential than ever. 

This webinar brings together two of the most well-informed voices on the topic: Sam Tetlow of Grant Engine and Deb Autor of Healthcare Innovation Catalysts. Together, they’ll discuss what companies must know to stay ahead, drawing on their ongoing conversations with government officials, regulators, and agency leaders and their primary experience in successfully navigating the new government landscape. 

Receive real-time intelligence on changes at the FDA, NIH, NSF, ARPA-H, and Dept Defense on regulatory policy shifts, federal funding updates, and strategic insight on how to thrive in a climate of uncertainty. Whether you’re actively preparing to approach the FDA, considering when and how to do that, preparing your next funding application, or planning your long-term funding strategy - this session will offer the context and direction to help you lead with confidence. 

We will focus on: 

• FDA’s expected direction under the new administration 

• Shifts in non-dilutive funding availability and agency budgets 

• Timelines, funding strategies, and compliance implications 

• How successful companies are adapting to current headwinds 

• What we’ve learned from 40+ federal conversations and counting 

Sam Tetlow is Founder & CEO of Grant Engine. Grant Engine has a proven model of delivering funding to leading life science companies through the NIH SBIR program as well as DARPA, BARDA and other DoD sources. Sam has successful experience as an entrepreneur and investor in life sciences companies such as EpiCypher (named best University Startup of 2016 by U.S. Congress), ILS Genomics, Immunologix, Gentris Corporation, and Tranzyme Pharma (IPO April, 2011) among others.

As a leader within companies Sam has a functional focus on product development, sales, finance and corporate development. Sam continues to build on his venture capital experience by investing into compelling companies as an Angel. Sam seeks results and has a proven track record.   Sam has generated a 5.8x return on invested capital, with 76% cash realization in his last 14 years of investing.

Sam holds a MBA from UNC Kenan-Flagler Business School (Beta Gamma Sigma, 2003) and a B.S. in Aerospace Engineering from Worcester Polytechnic Institute (Honors, 1993). He has been on Mt. Everest, is a former competitive triathlete, and an avid proponent of doing good while doing well.

Deb Autor has over 30 years of experience in regulatory, compliance, legal, and business strategy, including serving as Deputy Commissioner of the FDA, Director of Compliance at FDA/CDER, and leading global regulatory and quality functions at AstraZeneca and Mylan. Before FDA, Deb was a Trial Attorney at the U.S. Department of Justice, where she prosecuted dozens of civil and criminal cases on behalf of FDA. She is Chair of the FDA Alumni Association, and an expert advisor, board member, and decorated government leader educated at Harvard, Kellogg, BU, and Columbia. At Healthcare Innovation Catalysts, Deb’s multidisciplinary team of ex-FDA, industry, and academic experts combines strategic and technical expertise in regulatory affairs, clinical, quality, compliance, reimbursement, and federal partnerships. They are a catalyst for healthcare innovation.